Nanostructured lipid carriers-containing anticancer compounds: Preparation, characterization, and cytotoxicity studies

Drug Delivery

Volumn 14, Issue 2, 2007, Pages 61-67

  Bondì, Maria Luisa ^a   Craparo, Emanuela Fabiola ^b   Giammona, Gaetano ^b   Cervello, Melchiorre ^c   Azzolina, Antonina ^c   Diana, Patrizia ^b   Martorana, Anna ^b   Cirrincione, Girolamo ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

Author keywords

Antitumor Drugs; Controlled Release; Human Hepatocellular Carcinoma Cells; Human Prostate Carcinoma Cells; Nanostructured Lipid Carrier

Indexed keywords

8 CYANO 3,6 DIPHENYL 7 METHYL[2,1 D]PYRROLO[1,2,3,5]TETRAZIN 4 ONE; 8 CYANO 6 PHENYL 7 METHYL 3 (4 CHLOROPHENYL) [2,1 D]PYRROLO[1,2,3,5]TETRAZIN 4 ONE; ANTINEOPLASTIC AGENT; DRUG CARRIER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLLOID; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; ELECTROCHEMISTRY; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; PLASMA; SOLUBILITY;

EID: 33847052803     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540600739914     Document Type: Article

References (25)

1. Miura, H., Onishi, H., Sasatsu, M., and Machida, Y. 2004. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. J. Control. Rel. 97:101-113.
2. Mehnert, W., and Mader, K. 2001. Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug Del. Rev. 47:165-196.
3. Muller, R. H., Mader, K., and Gohla, S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50:161-177.
4. Lasic, D. D. 1998. Novel applications of liposomes. Tibtech 16:307-321.
5. Heath, T. H. 1988. Liposomes dependent drugs. In Liposomes as Drug Carriers: Trends and Progress. ed. Gregoriadis, G., San Francisco: Wiley. pp. 709-718.
6. Smith, A., and Hunneyball, I. M. 1986. Evaluation of polylactid as a biodegradabledrug delivery system for parenteral administration. Int. J. Pharm. 30:215-230.
7. Wissing, S. A., Kayser, O., and Muller, R. H. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Del. Rev. 56:1257-1272.
8. Muller, R. H., Radtke, M., and Wissing, S. A., 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Del. Rev. 54(1):S131-S155.
9. Muller, R. H., Radtke, M., and Wissing, S. A. 2002. Nanostructured lipid matrices for improver microencapsulation of drugs. Int. J. Pharm. 242:121-128.
10. Radtke, M., and Muller, R. H. 2001. NLC-nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs 2:97-138.
11. Jenning, V., Thunemann, A. F., and Gohla, S. H. 2000. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199:167-177.
12. Jenning, V., and Gohla, S., 2001. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencaps. 18:149-158.
13. Jores, K., Mehnert, W., Drechsler, M., et al. 2004. Investigation on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Rel. 95:217-227.
14. Diana, P., Barraja, P., Lauria, A., et al. 1999. Pyrrolo[2,1-d][1, 2,3,5]-tetrazines, a new class of azolotetrazines related to the antitumor drug temozolomide. Synthesis 2082.
15. Grever, M. R., Sherpartz, S. A., and Chabner, B. A. 1992. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19:622-638.
16. Monks, A. P., Scudiero, D. A., Skehan, P., et al. 1991. Feasibility of a high-flux anticancer drug screen utilizing a derived panel of human tumor cell lines in culture. J. Natl. Cancer Inst. 83:757-766.
17. Weinstein, J. N., Meyers, T. G., O'Connor, P. M., et al. 1997. An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349.
18. Diana, P., Barraja, P., Lauria, A., et al. 2003. Pyrrolo[2,1-d][1, 2,3,5]-tetrazine-4(3H)-ones, a new class of azolotetrazines with potent antitumor activity. Bioorg. Med. Chem. 11:2371-2380.
19. Plowman, J., Dykes, D. J., Hollingshead, M., et al., 1997. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; ed. Teicher B., Totowa, NJ: Humana Press. 101-125.
20. Hollingshead, M., Plowman, J., Alley, M. C., et al., 1999. The hollow fiber assay. Contrib. Oncol. 54:109-120.
21. Brigger, I., Dubernet, C., and Couvreur, P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 54:631-651.
22. Maeda, H., Wu, J., Sawa, T., et al. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 65:271-284.
23. Maeda, H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:189-207.
24. Noguchi, Y., Wu, J., Duncan, R., et al. 1998. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89:307-314.
25. Scholer, N., Hahn, H., Muller, R. H., and Liesenfeld, O. 2002. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 231:167-176.